|
KMID : 0614619930250030555
|
|
Korean Journal of Gastroenterology
1993 Volume.25 No. 3 p.555 ~ p.561
|
|
|
Prospective, Randomized, Controlled Trical with Camostat Mesilate(Foipan) in Patients With Chronic Pancreatitis
|
|
|
|
|
Abstract
|
|
|
In a prospective, randomized, double-blind. Controlled study on 21 patients with chronic pancreatitis, the effects of treatment with camostat metilate (Foipan(r)) were compared with those of placebo adminstration. Ten patients received camostat
mesilate
600 mg/d for 4 weeks, and 11 patients were enrolled as placebo controls.
The number of pain attacks per day in the camostat mesilate treatment group decreased from 4.5±0.7 during pre-treatment to 0.5±0.4, 0.2±0.2, and 0.2±0.2 during the 1st, 2nd, and 4th weeks respectively. In contrast, the number of pain attacks
for the
control patients changed from 4.1±1.1 during pre-treatment to 2.3±0.5, 1.0±0.4, and 0.6±0.5 during the 1st , 2nd, and 4th weeks respectively. The degree of the pain severity in the camostat mesilate group decreased form 3.0±0.4 during
pretreament
to 0.7±0.4, 0.3±0.5, and 0.5±0.3 during the 1st, 2nd, 4th weeks respectively, and that of the control group changed form 2.8±0.5 during pre-treatment to 1.7±0.4, 1.0±0.5, and 0.6±0.3 during the 1st, 2nd, and 4th weeks respectively.
Therefore,
there was a remarkable difference in the number of pain attackds and the degree of the pain severity between the camostat mesilate treatment group and the control group after initiation of the treatment (p<0.05). However, the degree of abdommal
cenderness, amount of analgesics consumption, and serum amylase levels did not differ between the camostat mesilate treatment group and the cotrol group (p>0.05). No significant adverse effects were observed in either goups. Thus it is concluded
that
camosta; mesilate is effective in alleviating the abdominal pain of patients with chronic pancreatitis and is very safe.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|
|